Efficacy and safety of Eribulin as the first line therapy for advanced or recurrent breast cancer patients without HER2 overexpression.
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2016
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 Jun 2015 Status changed from recruiting to completed, according to 2015 ASCO abstract.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Aug 2011 New trial record